Arch Biopartners
@archbiopartners.com did:plc:g74qpotcy3afobw4vovdonlv
Arch Biopartners is a therapeutic biotech company focused on developing novel, on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD).
Bei Bluesky seit
- Follower
- 54
- Folgt
- 65
- Posts
- 88
- Tage in Ranglisten
- 0
Zusammenfassung
Arch Biopartners (@archbiopartners.com) ist seit 22 April 2025 auf Bluesky. Das Konto hat 54 Follower, folgt 65 Konten und hat 88 Posts veröffentlicht.
Ranglisten-Platzierungen
Die besten Tage, an denen Posts dieses Kontos in Debyas Tagesliste kamen.
Dieses Konto war noch in keiner Tagesrangliste.
Zuletzt gelikte Posts
Öffentliche Likes aus dem Bluesky-Netzwerk.
What if kidney disease could be treated before it progresses to failure? @archbiopartners.com is advancing research into IL-32, a promising biological pathway linked to diabetic kidney disease, transforming patient care. @amdiabetesassn.bsky.social #ADASciSessions https://youtu.be/S9CppOv643s
Post anzeigenHow do fibrillary pathology and diabetes influence kidney function when they occur together? Dr. River Charles & Dr. Frank Boyd dive into this fascinating collision case in the newest #Collidescope episode. 👉 https://youtu.be/O4ylMrIHOh4 #nephsky #pathsky #diabetes #kidneypath
Post anzeigenPre-existing cardiovascular disease and hyperlipidemia and mortality in peritoneal dialysis pat - goo.gl/alerts/CQKs84 #GoogleAlerts
Post anzeigenPillars of #IgAN Treatment #GlomConHawaii 🌊 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/38398259/
Post anzeigen🩺 Are you an NNCC-certified nurse or tech and an @NKF member? You could receive $3,000 to continue your education through the CNNT Career Mobility Scholarship. Open through June 1! Apply Today: bit.ly/3S1kMj9 #Dialysis #MedEd #Nephrology
Post anzeigen
Blockierte Konten
Blockierungen sind auf Bluesky öffentlich.
Dieses Konto blockiert niemanden.